Federal Register of Legislation - Australian Government

Primary content

PB 53 of 2012 Determinations/Health as made
This determination amends the National Health (Listed drugs on F1 or F2) Determination 2010 (No. PB 93 of 2010) by adding five new listed drugs cabazitaxel, icatibant, mannitol, rasagiline and ticagrelor to F1. Moving five drugs from F1 to F2 hydroxychloroquine, lamivudine, latanoprost, pramipexole and topotecan and also moves one drug latanoprost with timolol, from the combination drug list to F2.
Administered by: Health
Registered 30 Jul 2012
Tabling HistoryDate
Tabled HR14-Aug-2012
Tabled Senate14-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No. 5)

Instrument number PB 53 of 2012

National Health Act 1953

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the
Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated              27            July   2012

 

 

 

 

 

 

 

 

 

ADRIANA PLATONA

 

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2012 (No. 5).

         (2)   This Determination may also be cited as PB 53 of 2012.

2              Commencement

                This Determination commences on 1 August 2012.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

[1]     Schedule 1, after item dealing with Busulfan

 

Insert

 

Cabazitaxel 

 

[2]     Schedule 1, after item dealing with Hydromorphone

 

Omit

 

Hydroxychloroquine 

 

[3]     Schedule 1, after item dealing with Ibuprofen

 

Insert

 

Icatibant 

 

[4]     Schedule 1, after item dealing with Lacosamide

 

Omit

 

Lamivudine 

 

[5]     Schedule 1, after item dealing with Lapatinib

 

Omit

 

Latanoprost 

 

[6]     Schedule 1, after item dealing with Losartan

 

Insert

 

Mannitol 

 

[7]     Schedule 1, after item dealing with Posaconazole

 

Omit

 

Pramipexole 

 

[8]     Schedule 1, after item dealing with Ranibizumab

 

Insert

 

Rasagiline 

 

[9]     Schedule 1, after item dealing with Tiaprofenic acid

 

Insert

 

Ticagrelor 

 

[10]   Schedule 1, after item dealing with Tocilizumab

 

Omit

 

Topotecan 

 

[11]   Schedule 2, after item dealing with Hydroxocobalamin

 

Insert

 

Hydroxychloroquine 

 

[12]   Schedule 2, after item dealing with Lactulose

 

Insert

 

Lamivudine 

 

[13]   Schedule 2, after item dealing with Lansoprazole

 

Insert

 

Latanoprost

Latanoprost with timolol 

 

[14]   Schedule 2, after item dealing with Potassium chloride with potassium bicarbonate

 

Insert

 

Pramipexole

 

[15]   Schedule 2, after item dealing with Topiramate

 

Insert

 

Topotecan

 

 

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See http://www.frli.gov.au.